Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 107.54% is 77% above its 1-year average of 60.80%, around the middle of its 1-year range (0.00%–204.00%).
76.88% above its 12-month average of 60.80%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
107.54%
GROSS MARGIN AVG TTM
60.80%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+76.88%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
+127.91%
vs the sector median at left
Allarity Therapeutics, Inc.
Market Cap
$15.63M
Gross Margin
107.54%
TTM Avg
60.80%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$16.37M
Gross Margin
0.00%
TTM Avg
-3731.89%
3Y Avg
-2384.22%
5Y Avg
-1567.12%
Market Cap
$15.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-33.27%
Market Cap
$17.24M
Gross Margin
-88.25%
TTM Avg
-11.22%
3Y Avg
9.24%
5Y Avg
11.19%
Market Cap
$16.41M
Gross Margin
21.95%
TTM Avg
11.59%
3Y Avg
17.76%
5Y Avg
20.87%
Market Cap
$15.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.45%
Market Cap
$15.20M
Gross Margin
95.88%
TTM Avg
95.90%
3Y Avg
96.27%
5Y Avg
96.83%
Market Cap
$14.28M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.63M | 107.54% | 60.80% | 0.00% | 0.00% |
| BioCardia, Inc. (BCDA)vs › | $16.37M | 0.00% | -3731.89% | -2384.22% | -1567.12% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | 0.00% | 0.00% | 0.00% | -33.27% |
| Dyadic International, Inc. (DYAI)vs › | $17.24M | -88.25% | -11.22% | 9.24% | 11.19% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.41M | 21.95% | 11.59% | 17.76% | 20.87% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | 0.00% | 0.00% | 0.00% | -2.45% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | 95.88% | 95.90% | 96.27% | 96.83% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | 0.00% | 0.00% | 0.00% | 0.00% |
| IN8bio, Inc. (INAB)vs › | $13.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | 64.68% | 63.93% | 63.08% | 61.52% |
Gross Margin
107.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 204.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | -410.92% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -4990.76% |
| 2019-03-31 | -3136.01% |
| 2018-12-31 | 20814.28% |
| 2018-09-30 | -33.80% |
| 2018-06-30 | -53.38% |
| 2018-03-31 | -89.15% |
| 2017-12-31 | -108.58% |
| 2017-09-30 | -130.82% |
| 2017-06-30 | 25.83% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | -991.87% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | -282.75% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | -80.49% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
